Lv3
390 积分 2021-04-02 加入
Prophylaxis of Pneumocystis Pneumonia in Immunocompromised Non-HIV-Infected Patients: Systematic Review and Meta-analysis of Randomized Controlled Trials
24天前
已完结
846. Pneumocystis Pneumonia in malignancy patients: Who is at risk?
24天前
已完结
Prophylaxis of Pneumocystis Pneumonia in Immunocompromised Non-HIV-Infected Patients: Systematic Review and Meta-analysis of Randomized Controlled Trials
24天前
已完结
Prophylaxis Against Pneumocystis Pneumonia
24天前
已完结
Prophylaxis Against Pneumocystis jirovecii Pneumonia in Adults
24天前
已完结
Outcomes in patients with multiple myeloma receiving salvage treatment after BCMA‐specific CAR‐T therapy: A retrospective analysis of LEGEND‐2
1个月前
已完结
Real-world outcomes of isatuximab with pomalidomide and dexamethasone for relapsed and/or refractory multiple myeloma
2个月前
已完结
The Risk and Reversibility of Osimertinib-related Cardiotoxicity in a Real-World Population
6个月前
已完结
Isatuximab, carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed, transplantation-eligible multiple myeloma (SKylaRk): a single-arm, phase 2 trial
8个月前
已完结
OAB-053: Mezigdomide (MEZI; CC-92480) in combination with dexamethasone (DEX) and bortezomib (BORT) or carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM)
1年前
已完结
皖公网安备34019202002308
